Abstract
Background: Oral anticoagulation (OAC) is the most effective treatment to prevent strokes in patients with atrial fibrillation (AF). Many older patients are not prescribed OAC. Objective: To explore which co-morbid conditions in older patients with AF have been associated with under-treatment with OAC, or were used as exclusion criteria for trials, or have been associated with increased risk of bleeding. Methods: A Pubmed search was conducted with the terms elderly, atrial fibrillation, stroke risk, bleeding risk, intracranial haemorrhage, cognition, fall risk, renal dysfunction, alcohol abuse, malignancy, polypharmacy, NSAID, under-treatment, under-use and under-prescription. Results: Higher age is associated with under-treatment. Patients with a higher risk of stroke show higher rates of bleeding complications. The associations of bleeding rates with possible contraindications are inconsistent. Discussion: Published bleeding rates reflect selection bias, describing mainly relatively healthy older patients. The use of stratification schemes for stroke risk and for bleeding risk will have to be implemented. Conclusion: The decision to prescribe OAC in older patients with AF remains a challenging task since bleeding risk is difficult to estimate reliably. Stratification schemes may be helpful.
Keywords: Geriatric, elderly, atrial fibrillation, under-treatment, anticoagulation, contraindications, major bleeding risk
Current Drug Safety
Title: Contraindications for Anticoagulation in Older Patients with Atrial Fibrillation: A Narrative Review
Volume: 5 Issue: 3
Author(s): Linda R. Tulner, Ingeborg M.J.A. Kuper, Jos P.C.M. van Campen, Melvin R. Mac Gillavry, Vincent I.H. Kwa, Cornelis H.W. Koks, Jos H.Beijnen and Desiderius P.M. Brandjes
Affiliation:
Keywords: Geriatric, elderly, atrial fibrillation, under-treatment, anticoagulation, contraindications, major bleeding risk
Abstract: Background: Oral anticoagulation (OAC) is the most effective treatment to prevent strokes in patients with atrial fibrillation (AF). Many older patients are not prescribed OAC. Objective: To explore which co-morbid conditions in older patients with AF have been associated with under-treatment with OAC, or were used as exclusion criteria for trials, or have been associated with increased risk of bleeding. Methods: A Pubmed search was conducted with the terms elderly, atrial fibrillation, stroke risk, bleeding risk, intracranial haemorrhage, cognition, fall risk, renal dysfunction, alcohol abuse, malignancy, polypharmacy, NSAID, under-treatment, under-use and under-prescription. Results: Higher age is associated with under-treatment. Patients with a higher risk of stroke show higher rates of bleeding complications. The associations of bleeding rates with possible contraindications are inconsistent. Discussion: Published bleeding rates reflect selection bias, describing mainly relatively healthy older patients. The use of stratification schemes for stroke risk and for bleeding risk will have to be implemented. Conclusion: The decision to prescribe OAC in older patients with AF remains a challenging task since bleeding risk is difficult to estimate reliably. Stratification schemes may be helpful.
Export Options
About this article
Cite this article as:
R. Tulner Linda, M.J.A. Kuper Ingeborg, P.C.M. van Campen Jos, R. Mac Gillavry Melvin, I.H. Kwa Vincent, H.W. Koks Cornelis, H.Beijnen Jos and P.M. Brandjes Desiderius, Contraindications for Anticoagulation in Older Patients with Atrial Fibrillation: A Narrative Review, Current Drug Safety 2010; 5 (3) . https://dx.doi.org/10.2174/157488610791698253
DOI https://dx.doi.org/10.2174/157488610791698253 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Gender Differences in Response to Therapy for Cardiovascular Diseases
Current Pharmacogenomics and Personalized Medicine Carbon Nanotube-Based Electrochemical Biosensing Platforms: Fundamentals,Applications, and Future Possibilities
Recent Patents on Biotechnology Therapeutic Angiogenesis in Ischemic Heart Disease: Gene or Recombinant Vascular Growth Factor Protein Therapy?
Current Gene Therapy Gastrointestinal Bleeding Associated With Warfarin and Rivaroxaban Therapy in Atrial Fibrillation Cases with Concomitant Coagulopathy
Cardiovascular & Hematological Disorders-Drug Targets Vitamins B1, B2, B3 and B9 – Occurrence, Biosynthesis Pathways and Functions in Human Nutrition
Mini-Reviews in Medicinal Chemistry Role of Pharmacotherapy in Cardiac Ion Channelopathies
Current Vascular Pharmacology Implication of Gut Microbiota in Human Health
CNS & Neurological Disorders - Drug Targets miR-126 as a Therapeutic Agent for Diabetes Mellitus
Current Pharmaceutical Design Implications of the Obesity Epidemic for Statin Therapy: Shifting Cholesterol Metabolism to a High Synthesis and Low Dietary Absorption State
Endocrine, Metabolic & Immune Disorders - Drug Targets The Effects of Pemafibrate in Japanese Patients with Type 2 Diabetes Receiving HMG-CoA Reductase Inhibitors
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial: (New Drug (LCZ696) for the Treatment of Heart Failure with Reduced Ejection Fraction After 10 Years. Can One Study Change the Guidelines?)
Current Vascular Pharmacology Application of VEGF Gene Therapy in Two Basic Fields of Plastic- Reparative Surgery: Tissue Reconstruction with Flaps and Peripheral Nerve Surgery
Recent Patents on Regenerative Medicine Pyrazolines: A Biological Review
Mini-Reviews in Medicinal Chemistry Bioprocess and Bioreactor: Next Generation Technology for Production of Potential Plant-based Antidiabetic and Antioxidant Molecules
Current Medicinal Chemistry The Complementary Roles of Imaging and ‘Omics’ for Future Anti-Atherosclerotic Drug Development
Current Pharmaceutical Design UKPDS Risk Engine, Decode and Diabetes PHD Models for the Estimation of Cardiovascular Risk in Patients with Diabetes
Current Diabetes Reviews The Etiology of Hypertension in the Metabolic Syndrome Part Two: The Gene-Environment Interaction
Current Vascular Pharmacology Mechanisms of Neuronal Damage and Neuroprotection Underlying Ischemia/Reperfusion Injury after Physical Exercise
Current Drug Targets Low Estimated Glomerular Filtration Rate is Associated with High Recurrence Rate and Poor Prognosis of Hemorrhage Stroke
Current Neurovascular Research A New Risk Chart of Acute Myocardial Infarction in Men by an Innovative Algorithm: A Pilot Study
Current Pharmacogenomics and Personalized Medicine